CRISPR/Cas 9 was used as a gene editing tool in clinical studies aiming to disrupt regulatory elements, such as the erythroid enhancer of the BCL11A gene or the BCL11A-binding elements present in the promoter of HBG1 and HBG2 genes, or to correct the point mutation observed in SCD patients. Here, BCL11A is linked to Schnyder corneal dystrophy.